AzTrials
AzTrials

Nutritional RequirementsNCT04286321

Achieving Nutritional Adequacy Of Vitamin K With An Egg/Plant-Based Food Pairing

A study testing Zero hard-boiled egg at 0 h, One hard-boiled egg at 0 h and Two hard-boiled eggs at 0 h in people with Nutritional Requirements, run by Ohio State University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Malnutrition of the fat-soluble nutrient vitamin K (phylloquinone; PQ) is problematic. Since PQ is rich in plant foods (e.g. spinach) that are mostly absent of accessible lipid, dietary patterns that can potentiate PQ bioavailability by pairing vegetables with lipid-rich foods have been emphasized. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Nutritional Requirements
What is being tested?
Zero hard-boiled egg at 0 h, One hard-boiled egg at 0 h and Two hard-boiled eggs at 0 h
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteUnited States
Study dates
1 Jun 2021to 15 Jul 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Body Mass Index (BMI) = 19-25 kg/m2
  • Normolipidemic (total cholesterol <240 mg/dL; triglyceride <150 mg/dL)
  • Fasting glucose <100 mg/dL
  • Normal hematocrit level (41%-50% for men and 36%-48% for women)
  • Normal hemoglobin level (13.5-17.5 g/dL for men and 12.0-15.5 g/dL for women)
  • No use of dietary supplements for >1 month
Show all 9Show fewer
  • No use of medications that affect lipid or glucose metabolism
  • Non-smoker
  • No history of gastrointestinal disorders

Who cannot join

  • Egg allergy
  • Alcohol intake > 2 drinks per day
  • Aerobic activity >7 h/wk
  • Body mass change >2 kg in the past 1 month
  • Women who are pregnant, lactating, or initiated or changed birth control in the past 3 month
  • Vegetarian

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Bruno Lab

    Columbus, Ohio, 43210

Other trials in United States

About this study

Malnutrition of the fat-soluble nutrient vitamin K (phylloquinone; PQ) is problematic. Since PQ is rich in plant foods (e.g. spinach) that are mostly absent of accessible lipid, dietary patterns that can potentiate PQ bioavailability by pairing vegetables with lipid-rich foods have been emphasized. The purpose of this study is to use deuterium-labeled spinach (containing stable isotopes of PQ) to validate eggs as a dietary tool to improve PQ bioavailability directly from a model plant food, and hence achieve nutrient adequacy. It is expected that compared with deuterium-labeled spinach alone, co-ingestion of eggs will increase plasma bioavailability of spinach-derived deuterium-labeled PQ without affecting time to maximal concentrations or half-lives. Further, phospholipid-rich egg yolk lipid will enhance nutrient bioavailability compared with vegetable oil. The outcomes will serve as the foundation for easy-to-implement message of public health importance in support of whole eggs and egg whites as part of a plant-based dietary pattern.

Read the detailed description

In the US, 43-63% of men and women do not meet recommended intakes for PQ. Dietary recommendations strongly encourage a diet rich in fruits and vegetables to meet dietary PQ requirements. However, PQ bioavailability from most plant foods is quite poor, thereby emphasizing a need for effective food pairings that can enhance the absorption and promote adequate status of these health-promoting nutrients. The objective of this study is to demonstrate that an effective food pairing of spinach with phospholipid lipid-rich eggs promotes intestinal absorption of spinach-derived PQ, and hence achieve nutrient adequacy. Our hypothesis is that the bioavailability of PQ from deuterium-labeled spinach will be potentiated by egg intake in a dose-dependent manner by increasing their secretion in intestinal-derived chylomicrons. Furthermore, phospholipid-rich whole eggs will enhance spinach-derived PQ bioavailability compared with vegetable oil, and will be most functionally responsible for the benefits of eggs to enhance nutrient absorption. Additionally, egg whites will more greatly promote nutrient bioaccessibility compared with spinach alone.

To test this, our specific aim is to assess egg-mediated improvements in PQ bioavailability by conducting a cross-over pharmacokinetic study in healthy men and women. In Study Arms 1-4, participants will ingest deuterium-labeled spinach (containing 500 μg PQ) with 0, 1, 2, or 3 hardboiled eggs (containing 0, 4.8, 9.6, or 14.4 g total fat, respectively). In Study Arm 5, participants will ingest spinach alone followed by 1 egg 3-hours later. In Study Arm 6, participants will ingest spinach with 1 egg followed by another egg 3-hours later. In Study Arm 7, participants will ingest spinach with two egg whites. In Study Arm 8, participants will ingest spinach with 9.6 grams of vegetable oil. Thus, Study Arms 1-4 will test the dose-dependent effects of eggs on PQ bioavailability, Study Arms 5-6 (with comparison to Study Arms 1 and 2) will test the 'timing'-dependent effects of eggs on PQ bioavailability, and Study Arms 7-8 will test the matrix effect on PQ bioavailability. Eucaloric diets will be controlled for PQ intakes for 3 d prior to and during the initial 24 h of each trial to minimize heterogeneity of pharmacokinetic responses. Spinach-derived deuterium-labeled PQ will be measured in plasma and isolated chylomicrons collected at timed intervals from 0-72 h post-meal ingestion, and biomarkers of antioxidant status and oxidative distress will be assessed at baseline (0 h) of each trial. Outcomes from this study are expected to establish that egg lipids substantially enhance plant-derived PQ bioavailability (based on AUC0-72 h, Cmax, and % estimated absorption) independent of any changes in oxidative distress.

The rationale for this study is that, by establishing the efficacy of eggs and egg yolk lipids to potentiate plant-derived fat-soluble nutrient bioavailability, a strong framework will exist for an easily implementable health-promoting food pairing strategy to overcome malnutrition of PQ.

Being tested
Zero hard-boiled egg at 0 h, One hard-boiled egg at 0 h, Two hard-boiled eggs at 0 h, Three hard-boiled eggs at 0 h, One hard-boiled egg at 3 h
Keywords
Vitamin K, Egg, Spinach

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Zero hard-boiled egg at 0 hOther

    No eggs will be consumed on test day along with spinach consumption

  • One hard-boiled egg at 0 hOther

    One egg will be consumed on test day along with spinach consumption

  • Two hard-boiled eggs at 0 hOther

    Two eggs will be consumed on test day along with spinach consumption

  • Three hard-boiled eggs at 0 hOther

    Three eggs will be consumed on test day along with spinach consumption

  • One hard-boiled egg at 3 hOther

    One egg will be consumed on test day three hours after spinach consumption

  • One hard-boiled egg at 0 h + One hard-boiled egg at 3 hOther

    Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption

  • Two egg whites at 0 hOther

    Two egg whites will be consumed on test day along with spinach consumption

  • Vegetable oil at 0 hOther

    9.6 grams of Vegetable oil will be consumed on test day along with spinach consumption

Study groups in NCT04286321
Study groupRoleWhat they receive
Zero hard-boiled eggExperimentalDeuterium-labeled spinach containing 500 μg PQ will be ingested alone prior to the 72-h pharmacokinetics trial.
Receives: Other: Zero hard-boiled egg at 0 h
One hard-boiled egg at 0 hExperimentalDeuterium-labeled spinach containing 500 μg PQ will be ingested along with one hard-boiled egg prior to the 72-h pharmacokinetics trial.
Receives: Other: One hard-boiled egg at 0 h
Two hard-boiled eggs at 0 hExperimentalDeuterium-labeled spinach containing 500 μg PQ will be ingested with two whole eggs (9.6 g fat) prior to the 72-h pharmacokinetics trial.
Receives: Other: Two hard-boiled eggs at 0 h
Three hard-boiled eggs at 0 hExperimentalDeuterium-labeled spinach containing 500 μg PQ will be ingested along with three hard-boiled eggs prior to the 72-h pharmacokinetics trial.
Receives: Other: Three hard-boiled eggs at 0 h
One hard-boiled egg at 3 hExperimentalDeuterium-labeled spinach containing 500 μg PQ will be ingested alone at 0 h prior to the 72-h pharmacokinetics trial followed by one hard-boiled egg 3 hours after spinach consumption.
Receives: Other: One hard-boiled egg at 3 h
One hard-boiled egg at 0 h + One hard-boiled egg at 3 hExperimentalDeuterium-labeled spinach containing 500 μg PQ will be ingested along with one hard-boiled egg at 0 h prior to the 72-h pharmacokinetics trial followed by one egg 3 hours after spinach consumption.
Receives: Other: One hard-boiled egg at 0 h + One hard-boiled egg at 3 h
Two egg whites at 0 hExperimentalDeuterium-labeled spinach containing 500 μg PQ will be ingested along with two egg whites prior to the 72-h pharmacokinetics trial.
Receives: Other: Two egg whites at 0 h
Vegetable oil at 0 hExperimentalDeuterium-labeled spinach containing 500 μg PQ will be ingested along with 9.6 grams of vegetable oil prior to the 72-h pharmacokinetics trial.
Receives: Other: Vegetable oil at 0 h

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Vitamin K Bioavailability

    Area under the curve of deuterium-labeled phylloquinone

    Measured: 0, 3, 4.5, 6, 7.5, 9, 12, 24, 36, 48, 72 hours post-ingestion of spinach

Secondary outcomes (5)
  1. Vitamin K Tmax

    Time to reach maximum plasma concentration of deuterium-labeled phylloquinone

    Measured: 0-72 hours post-ingestion of spinach

  2. Chylomicron Vitamin K

    Deuterium-labeled phylloquinone concentration in chylomicron

    Measured: 0, 3, 4.5, 6, 7.5, 9, 12 hours post-ingestion of spinach

  3. Estimated Absorption (%Dose) of Vitamin K

    Absorption of deuterium-labeled phylloquinone

    Measured: 0-72 hours post-ingestion of spinach

  4. Vitamin K Cmax

    Maximum plasma concentration of deuterium-labeled phylloquinone

    Measured: 0-72 hours post-ingestion of spinach

  5. Elimination Rate of Vitamin K

    Rate of plasma elimination of deuterium-labeled phylloquinone

    Measured: 0-72 hours post-ingestion of spinach

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Feb 2020
  2. Study start1 Jun 2021
  3. Primary completion15 Jul 2024
  4. Study completion15 Jul 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04286321
Sponsor's protocol ID
2019H0504-B
Status last verified
May 2025
First submitted
22 Feb 2020
Last updated
3 Jun 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Zero hard-boiled egg at 0 h, One hard-boiled egg at 0 h and Two hard-boiled eggs at 0 h in people with Nutritional Requirements, run by Ohio State University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Vitamin K Bioavailability (time frame: 0, 3, 4.5, 6, 7.5, 9, 12, 24, 36, 48, 72 hours post-ingestion of spinach). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2025; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in